HBW Regulatory News: Canadian OTC Firm Warned On GMPs, Homeopathic Guidance Comment Extended

FDA says Apollo Health And Beauty Care isn't meeting GMP requirements; and comment period on FDA draft guidance for oversight of homeopathic industry extended through March 23.

Apollo baby line
Apollo Health And Beauty Care's line of products that the FDA says are made in procedures non-compliant with drug GMp reuqirements include children's anad baby soaps, shampoos, sanitizers and bubble baths.

Canadian contract manufacturer Apollo Health And Beauty Care Inc. promotes itself as a personal care product provider but the US Food and Drug Administration considers its products OTC drugs and says the firm isn't meeting good manufacturing practices requirements. In a warning letter published 7 January following an inspection in August, the FDA Center for Drug Evaluation and Research's offices of manufacturing quality and compliance instructed the North York, ON, firm to provide information including results from a comprehensive investigation into the extent of the inaccuracies in its data records and reporting, including results of review for drugs distributed to the US and a detailed description of the scope and root causes of its data integrity lapses; and a current risk assessment of the potential effects of the observed failures on the quality of its drugs, including "analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations."

The warning submitted on 23 December, after the firm's response submitted in September failed to state details on corrective...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

Portfolios In Large US Food Industry Merger Cleared By FTC Include Nutritional Supplements

 

FTC decision, says Bureau of Competition director Daniel Guarnera, influenced by both companies marketing different lines in different countries, limiting the number of similar products in the same categories the combined firm would offer.

EU Industry Wants EFSA Changes To Support Innovation

 
• By 

Prominent trade groups call on the European Commission to improve risk assessment of innovative food products by making changes to processes at the European Food Safety Authority.

US FDA Clarifies Success For An NDI Notification Fits Only The Notifier’s Ingredient

Along with two instructional videos, FDA provides fact sheet detailing common problems with NDINs while supplement industry awaits guidance on two hurdles for clearing the NDIN process, providing identity information and evidence of safety for ingredients.

AESGP Annual Meeting: Harmonizing EU VMS Max Levels Could Cost Sector Over €200m

 
• By 

Limited capacity and a two-to-three year timescale for reformulation could mean that many VMS supplements disappear from the market, warns EPPA partner Alexandra Bocquillion, speaking at the AESGP Annual Meeting in Warsaw, Poland.

More from Policy & Regulation

US FDA Clarifies Success For An NDI Notification Fits Only The Notifier’s Ingredient

Along with two instructional videos, FDA provides fact sheet detailing common problems with NDINs while supplement industry awaits guidance on two hurdles for clearing the NDIN process, providing identity information and evidence of safety for ingredients.

Price To Resolve US Hemp Dilemma Too High In House Appropriators’ FY 2026 FDA Spending Bill

 

Provisions in bill approved by Agriculture, Rural Development, FDA and Related Agencies Subcommittee aren’t likely to pass largely because they set a price too high for delta-8 THC and other ingredients to meet the definition of hemp as a de-scheduled substance.

AESGP Annual Meeting: Harmonizing EU VMS Max Levels Could Cost Sector Over €200m

 
• By 

Limited capacity and a two-to-three year timescale for reformulation could mean that many VMS supplements disappear from the market, warns EPPA partner Alexandra Bocquillion, speaking at the AESGP Annual Meeting in Warsaw, Poland.